Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Acrivon Therapeutics has raised $130.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2024.
Acrivon Therapeutics's investors include RA Capital Management, Wellington Management, Sands Capital Ventures, New Enterprise Associates, Perceptive Advisors.
Acrivon Therapeutics is headquartered in Cambridge, United States.
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Acrivon Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Acrivon Therapeutics — Funding & Investors." VCBacked, April 9, 2024, https://www.vcbacked.co/company/acrivon-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). Acrivon Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/acrivon-therapeutics
{{cite web |title=Acrivon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/acrivon-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated